Niigata University Team Reports Novel Treatment For Idh2-mutant Brainstem Glioma

A group led by nan Department of Neurosurgery astatine nan Brain Research Institute, Niigata University, has successfully treated a diligent pinch a brainstem glioma harboring a uncommon IDH2 mutation. The diligent initially presented pinch a gradual nonaccomplishment of proceeding successful nan near ear, and MRI showed a lesion astatine nan near broadside of nan brainstem, adjacent nan guidelines exit area of nan near acoustic nerve. Initially, a brainstem glioma pinch H3K27M mutation was suspected.

However, nan gradual objective people and different location of nan brainstem glioma were considered atypical. The diligent underwent magnetic resonance spectroscopy successful which 2-hydroglutarate, a marker for IDH mutation, was evident. Subsequently, nan diligent underwent a surgical biopsy, and pathological study revealed a uncommon IDH2 mutation. Although astir brainstem gliomas pinch H3K27M mutation person an unmethylated MGMT promoter and frankincense are resistant to temozolomide, astir 70% of IDH-mutant astrocytomas are known to person a methylated MGMT promoter and are delicate to temozolomide.

A squad led by Dr. Manabu Natsumeda successfully treated nan diligent pinch temozolomide and radiation, and nan tumor dramatically shrank, and surprisingly, nan patient's proceeding improved. The diligent has been disconnected curen aft 1 twelvemonth of attraction temozolomide treatment, but nan tumor has not relapsed. "We were fortunate to observe IDH mutation successful this patient, aliases other we would not person utilized temozolomide. This lawsuit illustrates nan value of screening by MRS for IDH mutation and a safe biopsy to find nan optimal treatment." explains Dr. Natsumeda. The lawsuit study was published online successful nan diary Frontiers successful Oncology connected July 8, 2025.